Latvija - latviešu - Zāļu valsts aģentūra

novo nordisk a/s, denmark - estradiolum hemihydricum, norethisteroni acetas - apvalkotā tablete - 1 mg/0,5 mg

Latvija - latviešu - Zāļu valsts aģentūra

novo nordisk a/s, denmark - estradiolum hemihydricum, norethisteroni acetas - apvalkotā tablete - 1 mg/0,5 mg

Latvija - latviešu - Zāļu valsts aģentūra

novo nordisk a/s, denmark - estradiolum, norethisteroni acetas - apvalkotā tablete - 1 mg/0,5 mg

Latvija - latviešu - Zāļu valsts aģentūra

novo nordisk s.p.a., italy - estradiolum, norethisteroni acetas - apvalkotā tablete - 1 mg/0,5 mg

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - trīs no šiem attīrīts, inaktivēta mutes un nagu sērgas vīrusa celmiem: o1 manisa ≥ 6 pd50*; o1 bfs ≥ 6 pd50*; o taivāna 3/97 ≥ 6 pd50*; a22 irākas ≥ 6 pd50*; a24 cruzeiro ≥ 6 pd50*; turcija 14/98 ≥ 6 pd50*; Āzijas 1 Šamir ≥ 6 pd50*; sat2 saūda arābija ≥ 6 pd50*; * pd50 – 50% aizsardzības deva liellopiem, kā aprakstīts tālr eur. monogrāfijas 0063. - imunoloģiskie līdzekļi - pigs; cattle; sheep - lai samazinātu klīniskās pazīmes, liellopu, aitu un cūku aktīvai imunizācijai no 2 nedēļu vecuma pret mutes un nagu sērgu.

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated feline panleucopenia virus (pli iv), felv recombinant canarypox virus (vcp97) - immunologicals par kaķveidīgo, - kaķi - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs ;against feline panleucopenia to prevent mortality and clinical signs;against leukaemia to prevent persistent viraemia and clinical signs of the related disease. onsets of immunity are 1 week after primary vaccination course for rhinotracheitis, calicivirus and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component. the duration of immunity is one year after the last re-vaccination for the feline leukaemia component, and one year after primary vaccination course and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated chlamydophila felis (905 strain), attenuated feline panleucopenia virus (pli iv) - immunologicals par kaķveidīgo, - kaķi - active immunisation of cats aged eight weeks and older:• against feline viral rhinotracheitis to reduce clinical signs;• against calicivirus infection to reduce clinical signs;• against chlamydophila felis infection to reduce clinical signs;• against feline panleucopenia to prevent mortality and clinical signs. imūnsistēmas sākums ir pierādīts vienu nedēļu pēc primārās vakcinācijas kursa rinotraheīta, kalicivīrusa, chlamydophila felis un panleikopēnijas sastāvdaļām. the duration of immunity is one year after the last re-vaccination for the chlamydiosis component, and oneyear after primary vaccination and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated feline panleucopenia virus (pli iv), felv recombinant canarypox virus (vcp97), attenuated chlamydophila felis (905 strain) - immunologicals par kaķveidīgo, - kaķi - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs;against chlamydophila felis infection to reduce clinical signs;against feline panleucopenia to prevent mortality and clinical signs;against leukaemia to prevent persistent viraemia and clinical signs of the related disease. onsets of immunity are 1 week after primary vaccination course for rhinotracheitis, calicivirus, chlamydophila felis and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component. the duration of immunity is one year after the last re-vaccination for the chlamydiosis and feline leukaemia components, and one year after primary vaccination course and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

Latvija - latviešu - Pārtikas un veterinārais dienests, Zemkopības ministrija

merial, francija - inaktivēta Ņūkāslas slimības vīrusa, inaktivēta infekcijas, bronhīts vīruss, inaktivēta putnu saslimšanu vīrusu, inaktivēta olu piliens sindroms vīruss - eļļas - ūdens emulsija injekcijām - cāļi

Latvija - latviešu - Pārtikas un veterinārais dienests, Zemkopības ministrija

intervet international bv, nīderlande - inaktivēta infekcijas, bronhīts vīrusu serotipu massachusetts, celms m41, inaktivēta Ņūkāslas slimības vīruss, celms klons 30, inaktivēta infekcijas, bronhīts vīruss, celms 249g, inaktivēta putnu saslimšanu vīruss, celms, bet 1#8544, inaktivēta olu piliens sindroma vīrusu " 76 celms bc14 - emulsija injekcijām - vistas